Survey development
physician-informed
The Healthcare Provider Growth Hormone Treatment Experience Survey was developed by a team comprising representatives from the study sponsor and experts in patient-centered outcomes research. The initial content of the survey was informed by examination of the results of a literature review (The final survey is a 14-item questionnaire, designed for online administration, that assesses physicians’ experiences, preferences, and satisfaction with the use of once-weekly somatrogon compared with once-daily rhGH. Seven of these 14 items include open-ended, free-text fields in which physicians can describe why they chose their answer. The final survey questionnaire is provided in the online Along with the survey, two additional study forms (physician-informed consent form [P-ICF] and clinician screener and demographic form [CS-DF]) were developed and programmed for electronic administration via a Health Insurance Portability and Accessibility Act (HIPAA)-compliant online platform – SurveyMonkey.Pediatric endocrinologists from 55 sites in 19 countries who previously participated in the phase III study (NCT02968004) were contacted with information about the study; those physicians who had been involved in the development of the survey were excluded from participation. Interested pediatric endocrinologists were provided with a secure hyperlink containing the P-ICF and CS-DF. First, physicians were asked to read and complete the P-ICF, and those who consented to participate in the study (via the P-ICF) were directed to complete the CS-DF to confirm their eligibility for the survey. Once confirmed, they were granted access to answer the survey. To minimize missing data, each survey question had to be completed before the next question was made available. Physicians were able to move between questions, as needed, to review and revise previous responses. Physicians who completed the survey were compensated for their time spent, based on the fair market value rate for the physician’s country.